Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096999 · ClinicalTrials.gov registry record
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
A clinical trial of Metastatic Castration-resistant Prostate Carcinoma, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT07096999: Recruiting study of Metastatic Castration-resistant Prostate Carcinoma, sponsored by University of Michigan Rogel Cancer Center.
NCT07096999 is a study of Metastatic Castration-resistant Prostate Carcinoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 60 participants, above the 51-participant average among 8 other Metastatic Castration-resistant Prostate Carcinoma trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07096999, a study of Metastatic Castration-resistant Prostate Carcinoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Primary Outcome
Association between absorbed dose and effect (response/toxicity) following 177Lu-RLT
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2031-01-23 |
What NCT07096999 shows while recruiting
NCT07096999 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, above the 51-participant average among 8 other Metastatic Castration-resistant Prostate Carcinoma trials with a reported enrollment target (18% higher).
The record links to 1 condition, with Metastatic Castration-resistant Prostate Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07096999 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07096999 about?
NCT07096999 is a clinical study titled "SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy". This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
What is the current status of trial NCT07096999?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-01-23. Estimated completion is 2031-01-23.
What conditions does trial NCT07096999 study?
This clinical trial studies the following conditions: Metastatic Castration-resistant Prostate Carcinoma.
What interventions are being tested in trial NCT07096999?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07096999?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096999 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-resistant Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07096999's enrollment target sits among peer trials
60 3rd of 8 higher than 6 of 8 other Metastatic Castration-resistant Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-resistant Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
RECRUITING · Phase 4
-
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RECRUITING · Phase 1
-
Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
RECRUITING · Phase 1
-
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
RECRUITING · Phase 1
-
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
RECRUITING · Phase 2
-
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI